Condiciones de salud que cúrcuma puede ayudar a apoyar.
Curcumin, the active compound in turmeric, has shown promise in clinical trials for reducing abdominal discomfort and IBS symptoms through anti-inflammatory and gut microbiome-modulating effects. A 2024 observational study in 146 IBS patients found combined berberine/curcumin supplementation reduced abdominal discomfort scores by 47.2%. Systematic reviews confirm mechanistic and preliminary clinical potential.
Curcumin, the bioactive polyphenol in turmeric, has demonstrated antimicrobial activity against Mycobacterium abscessus in animal studies and against MRSA in vitro, supported by peer-reviewed research including a 2025 ASM study. Anti-inflammatory mechanisms via NF-κB suppression are well-documented.
Curcumin, the primary polyphenol of turmeric (Curcuma longa), has anti-inflammatory and antibacterial properties relevant to acne. A 2025 PMC clinical study evaluated a topical gel containing curcumin and clove oil vs. clindamycin in 31 participants with mild-to-moderate acne. Curcumin has been identified among plant-derived nutraceuticals with acne-relevant antioxidant, anti-inflammatory, and antibacterial properties in multiple systematic reviews.
Curcumin from turmeric (Curcuma longa) inhibits NF-κB and MAPK signaling pathways, reducing Th2 cytokine production, eosinophil infiltration, and airway inflammation relevant to respiratory allergies. Clinical studies demonstrate antioxidant activity in allergic rhinitis patients. A comprehensive 2025 systematic review (MDPI Nutrients) confirmed curcumin improves allergic rhinitis and dermatitis despite limited bioavailability. Turmeric has a long traditional use in Ayurvedic and traditional Chinese medicine for respiratory conditions.
Curcumin has been tested in ALS via a pilot randomized clinical trial using a nanocurcumin formulation added to riluzole. The 12-month double-blind trial (n=54) reported significantly improved survival probability in the nanocurcumin group (3.7% events vs. 22.2% in placebo, p=0.036), though functional scores did not differ. Preclinical data show curcumin protects motor neurons from TDP-43 toxicity and oxidative damage.
Curcumin, the active polyphenol of turmeric, has a scoping review (PMC 2025) of 19 clinical trials showing 89% improved wound healing outcomes vs. placebo or conventional care. Its anti-inflammatory and antimicrobial properties are directly mechanistically relevant to anal fissure healing. It is cited in Ayurvedic and evidence-based databases specifically for anal fissure and fistula support.
Curcumin, the principal polyphenol from Curcuma longa, has well-documented antioxidant activity supported by multiple meta-analyses of randomized controlled trials (RCTs) in humans. Clinical evidence shows it significantly reduces malondialdehyde (MDA), a lipid peroxidation marker, and raises enzymatic antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase. Its primary mechanistic pathway involves activation of the Nrf2-Keap1 signaling axis, which upregulates endogenous antioxidant response elements. Bioavailability is limited but can be enhanced by co-administration with piperine.
Curcumin significantly improves endothelial function as measured by flow-mediated dilation (FMD). A double-blind, placebo-controlled RCT showed 200 mg/day curcumin for 8 weeks produced a clinically significant 3.0% improvement in FMD in healthy adults. A further PMC study showed curcumin improves endothelial function in middle-aged adults by increasing NO bioavailability and reducing oxidative stress. A 2024 umbrella meta-analysis confirmed modest improvements in diastolic BP.
Curcumin is the primary polyphenolic curcuminoid from turmeric, shown in multiple RCTs and meta-analyses to reduce pain and improve function in knee osteoarthritis, with a large effect size in the 2017 systematic review of 69 OA supplement RCTs. It acts via NF-κB, COX-2, and 5-LOX inhibition.
Curcumin, the principal polyphenol of turmeric, inhibits NF-κB and MAPK signaling pathways that drive asthmatic airway inflammation. A combination trial including curcumin, Boswellia, and licorice root showed improvements in asthma patients. A 2025 systematic review confirmed curcumin inhibits NF-κB/MAPK signaling and improves allergic airway conditions.
Curcumin, the primary bioactive of turmeric, has been studied in over 30 randomized controlled trials across 10 autoimmune diseases. A 2022 meta-analysis found improvements in ulcerative colitis, rheumatoid arthritis, psoriasis, Crohn's disease, multiple sclerosis, and SLE. It modulates immune cell activity including T cells, B cells, macrophages, and NF-κB signaling.
Curcumin, the primary bioactive curcuminoid of turmeric, has documented efficacy in managing low back pain and musculoskeletal inflammation in RCTs. It inhibits COX-2, NF-κB, and 5-LOX pathways. Double-blind RCTs including a 90-day trial in chronic LBP patients (n=90) showed significant reductions in pain, disability, and inflammatory biomarkers versus placebo.
Curcumin, the principal bioactive of turmeric, has demonstrated potent anti-inflammatory, antioxidant, and anti-HSV activity in preclinical studies. A 2021 proposal in JEL Sciences formally proposed curcumin (via turmeric) as a Bell's palsy adjunct, citing its neuroprotective and antiviral properties against HSV. Life Extension's Bell's palsy protocol lists curcumin as a recommended nutrient for managing the inflammatory response in the condition.
Curcumin is the polyphenol bioactive in turmeric with well-documented antithrombotic, anticoagulant, and fibrinolytic properties. It inhibits platelet aggregation via arachidonic acid and TXA2 pathway suppression. A 2017 PubMed review comprehensively documented its mechanisms in hemostasis, anticoagulation, and fibrinolysis.
Curcumin, the primary bioactive compound in turmeric, has been evaluated in multiple RCTs for T2DM. It reduces fasting blood glucose and HbA1c, improves insulin sensitivity, and has anti-inflammatory effects relevant to metabolic disease. A systematic review and meta-analysis confirms significant glycemic benefits.
Curcumin is included in the 2025 Frontiers in Pharmacology PROSPERO-registered systematic review on chronic bronchitis. A 2026 Nutrients review rated Curcuma longa (curcumin source) as having robust clinical evidence for RTIs. It inhibits NF-κB, reduces bronchial cytokine production, and suppresses mucin gene expression and goblet cell hyperplasia relevant to bronchitis pathology.
Curcumin, the principal bioactive polyphenol in turmeric, inhibits COX-2 and 5-lipoxygenase and suppresses NF-κB, reducing joint inflammation and pain. Ten RCTs document improvements in arthritis pain and function comparable to NSAIDs. Podiatric specialists cite curcumin as the most evidence-backed natural anti-inflammatory for bunion-associated first metatarsophalangeal joint pain.
Curcumin, the principal bioactive of turmeric, has substantial preclinical evidence for burn wound healing, including animal studies showing reduced wound size, accelerated re-epithelialization, and decreased inflammation compared to silver sulfadiazine controls. It has been identified as a principal active ingredient in TCM burn treatment and is included in biopolymeric wound dressings in current research. Mechanisms include antioxidant, anti-inflammatory, and collagen-modulating actions.
Curcumin is the primary bioactive in turmeric explicitly cited by the Arthritis Foundation for treating bursitis. It inhibits NF-κB, COX-2, 5-LOX, and pro-inflammatory cytokines. A 2016 systematic review found 1,000 mg/day reduced OA pain comparably to NSAIDs. Traditional Ayurvedic use for joint inflammation is well-documented.
Curcumin, the principal polyphenol of turmeric, demonstrates antifungal activity against multiple Candida strains including nystatin-resistant and fluconazole-resistant isolates. Multiple in vitro studies confirm MIC activity against C. albicans, biofilm inhibition, and reduction of virulence factor secretion. It synergizes with standard antifungals.
Curcumin, the principal bioactive polyphenol of turmeric, has documented antifungal activity against multiple Candida species in vitro, including fluconazole-resistant strains. A 2009 PubMed study found curcumin more efficient than fluconazole in inhibiting Candida adhesion to human buccal epithelial cells. A 2023 study confirmed activity against nystatin-resistant C. albicans.
Curcumin has been evaluated in multiple RCTs and two systematic reviews for recurrent aphthous stomatitis (RAS). A 2020 systematic review (PubMed PMID 32893718) found curcumin has potential benefits in alleviating pain and accelerating healing in RAS, based on 8 included studies (n=439 subjects). A 2021 systematic review (PMID 34331693) further confirmed curcumin's anti-inflammatory and antibacterial role in oral disease treatment. Formulations studied include 1% curcumin nanomicelle gel and 2% plant-based curcumin gel.
Curcumin has antioxidant, anti-inflammatory, analgesic, and neuroprotective properties investigated in CTS. A 2024 double-blind, placebo-controlled RCT of topical curcumin gel in 70 CTS patients showed significant improvements in symptom severity and functional status scores. Oral curcumin in combination formulas also significantly reduced CTS-related neuropathic pain in additional clinical trials.
Curcumin is the primary bioactive polyphenol of turmeric, inhibiting NF-κB, COX-2, 5-LOX, and inflammatory cytokines (IL-1β, TNF-α, MMPs) that drive cartilage degradation. A landmark comparative RCT (Kuptniratsaikul et al. 2014, n=367 knee OA patients) found curcumin extract as effective as ibuprofen 1200 mg/day for knee pain relief with better GI tolerability. A 2021 meta-analysis of 10 RCTs confirmed curcuminoids significantly reduced WOMAC pain and stiffness, and ESCEO guidelines recognize curcuminoids as an OA nutraceutical.
Curcumin, the main active polyphenol in turmeric, suppresses HPV16/18 oncoproteins E6/E7 and restores p53/pRb function in cervical cancer cells in vitro. Multiple RCTs are underway: a Baylor Research Institute trial tests 500 mg twice daily orally for CIN3, and a prospective RCT tests intravaginal curcumin (2000 mg weekly) for LSIL/HSIL. No completed human clinical trial data for cervical dysplasia regression have been published, but preclinical evidence is robust.
Curcumin modulates genes involved in cholesterol synthesis including LDL receptor mRNA and HMG-CoA reductase expression. A meta-analysis of RCTs confirmed significant TC, LDL-C, and TG reductions. One human study of 500 mg/day curcumin showed HDL increased 29% and TC fell 12%.
Curcumin, the principal polyphenol of turmeric (Curcuma longa), has robust clinical and mechanistic evidence supporting its role in reducing chronic inflammation. Multiple meta-analyses of randomized controlled trials demonstrate significant reductions in key inflammatory biomarkers—CRP, IL-6, and TNF-α—following curcumin supplementation. Its core mechanism involves inhibition of the NF-κB signaling pathway and downstream pro-inflammatory cytokine cascades. A key limitation across studies is curcumin's inherently poor bioavailability, which has prompted the development of enhanced formulations (e.g., piperine co-administration, nanoparticles, phospholipid complexes).
Curcumin, the principal bioactive compound in turmeric, inhibits NF-κB and COX-2 inflammatory pathways. Multiple RCTs show it reduces osteoarthritis pain comparably to ibuprofen, with better GI tolerability. Both Ayurvedic tradition and modern systematic reviews support its use for chronic inflammatory pain.
Curcumin, the primary bioactive polyphenol of turmeric, supports vascular circulation by improving endothelial function, reducing arterial stiffness, inhibiting platelet aggregation, and exerting anti-inflammatory effects on vascular walls. A 2017 meta-analysis of RCTs confirmed curcumin supplementation significantly improved flow-mediated dilation (FMD) in patients with metabolic syndrome and other cardiovascular risk conditions.
Curcumin, the primary polyphenol from Curcuma longa, has been studied in multiple human RCTs for age-related cognitive decline, with some showing domain-specific benefits (particularly working memory in healthy older adults) but inconsistent results overall. A 2025 meta-analysis of 10 RCTs found no significant effect on global cognition (SMD = 0.14), while preclinical animal models show strong, consistent benefit. Poor oral bioavailability of standard curcumin formulations is widely cited as a key limiting factor, and enhanced-bioavailability preparations have produced more positive results in short-term trials. Evidence is promising but not yet conclusive.
Multiple RCTs and systematic reviews support curcumin as adjunctive therapy for ulcerative colitis (UC). A 2024 meta-analysis of 8 RCTs (482 patients) found adjunctive curcumin significantly improved clinical remission (RR=2.33, 95% CI: 1.25–4.34). It works via NF-κB inhibition and blockade of TNF-α binding, reducing mucosal inflammation.
Curcumin, the primary bioactive polyphenol of turmeric, reduces neuroinflammation, oxidative stress, and promotes BDNF upregulation — all key targets in concussion recovery. Animal TBI models consistently show curcumin improves cognitive recovery and reduces lesion size. A comprehensive 2024 meta-analysis (2000–2023 literature) identified curcumin alongside omega-3, vitamin D, and B-complex as among the top supplements showing promise in TBI management. A 2022 Frontiers in Nutrition systematic review confirms curcumin's effectiveness in improving neurological and molecular recovery after mTBI.
Curcumin, the primary bioactive polyphenol in turmeric, has been evaluated in COPD RCTs. A 2025 systematic review and meta-analysis found curcumin (200–500 mg/day) significantly reduced systolic blood pressure and improved FEV1 (SMD=−0.82) compared to placebo in COPD patients. It is recommended as an adjuvant option in this review. Bioavailability is low without enhanced formulations.
Curcumin (the principal polyphenol in turmeric/Curcuma longa) has been evaluated in multiple RCTs and a 2024 meta-analysis of 13 placebo-controlled RCTs in IBD including Crohn's disease. It inhibits NF-κB and suppresses TNF-α and IL-6. A pilot study showed clinical improvement as add-on therapy in five CD patients. Evidence is strongest for UC but CD-specific signals are promising.
Curcumin (from turmeric/Curcuma) is an anti-melanogenic compound listed among naturally derived topical depigmenting agents with significant benefits in periorbital hyperpigmentation management. A 2025 PMC-indexed clinical study (PMC12235579) used a formulation containing curcuma oily extract as an active, achieving a 47.94% reduction in under-eye hyperpigmentation over 6 weeks. Curcumin inhibits tyrosinase and melanin synthesis by suppressing MITF expression.
Curcumin, the primary bioactive compound of turmeric, has been evaluated in multiple RCTs for depression. A 2025 meta-analysis of 15 RCTs (n=1,123) found a statistically significant reduction in depressive symptoms (SMD = −0.65). It modulates neuroinflammation, HPA axis, BDNF, and multiple neurotransmitter systems. A 2017 meta-analysis also concluded curcumin is safe and efficacious in depressed patients.
Curcumin (from turmeric) has been evaluated in multiple dermatological RCTs. A systematic review of 18 RCTs found curcumin showed Grade B recommendation for psoriasis and pruritus, and Grade C-D for radiation dermatitis. It inhibits NF-κB and pro-inflammatory cytokines. Evidence for radiation dermatitis is specifically noted in clinical literature.
Curcumin has been specifically studied as a natural anti-inflammatory agent in diverticular disease. A 30-day longitudinal study of a curcumin-Boswellia phytosome formulation in SUDD patients demonstrated significant reduction in gastric pain. Animal models show curcumin reduces TNF-α, an inflammatory cytokine directly implicated in diverticular disease and acute diverticulitis.
An 8-week prospective randomized double-blind placebo-controlled RCT (n=155 DED patients) using curcumin 200 mg + lutein + zeaxanthin + vitamin D3 met both primary DED endpoints (Schirmer and OSDI, p<0.001). Curcumin reduces pro-inflammatory cytokines in corneal epithelial cells, inhibits NF-κB, and reduces oxidative stress and MMP-9 in ocular surface models.
Curcumin, the primary bioactive compound in turmeric, has anti-inflammatory and antioxidant properties mechanistically relevant to eczema. An open clinical trial in 42 atopic dermatitis patients found those adding oral curcumin to standard care showed improved outcomes. A 2016 review of 10 studies found significant skin disease improvement with curcumin.
Curcumin, the principal polyphenol of turmeric, has demonstrated anti-inflammatory, anti-angiogenic, and estradiol-suppressing effects on endometrial cells in vitro and in animal models. A 2025 randomized double-blind controlled trial showed 80 mg nanomicellar curcuminoids added to dienogest significantly improved pain, quality of life, and sexual function over 8 weeks. An earlier triple-blind RCT (68 women, 2022) found no significant effect on pain, indicating mixed clinical results.
Curcumin (from turmeric) has been listed in multiple recent systematic reviews and narrative reviews as a nutraceutical investigated for FM symptom management, primarily via anti-inflammatory and antioxidant mechanisms. A 2025 narrative review (PMC) cited curcumin among supplements potentially improving FM symptoms, and a 2025 Drug Topics review identified curcumin among key nutraceuticals for FM pain. Preclinical neuropathic pain models show curcumin alleviates pain behaviors and restores neuronal integrity.
Curcumin is the principal bioactive curcuminoid of turmeric with extensive RCT evidence for reducing OA pain, joint stiffness, and physical functional limitation. A 2025 network meta-analysis (39 RCTs, 4,599 KOA patients) confirmed curcumin demonstrated benefits in joint function outcomes and was ranked among the most effective supplements. Multiple systematic reviews confirm it reduces inflammatory markers relevant to joint mobility.
Curcumin was tested in a 2025 pilot RCT (n=40 eyes, University of Siena) in a multi-ingredient oral supplement for symptomatic vitreous floaters post-Nd:YAG capsulotomy, with significant improvements in floater perception and contrast sensitivity versus standard therapy. Its anti-inflammatory (NF-κB inhibition) and antioxidant properties are the proposed mechanism.
Curcumin inhibits NF-κB/MAPK signaling, enhances gut barrier function, and has demonstrated improvements in allergic rhinitis and dermatitis. It reduces Th2 cytokine production and IgE levels in preclinical allergy models. A 2025 comprehensive review confirmed curcumin's anti-allergic mechanisms and early clinical evidence, though bioavailability remains a challenge.
Curcumin, the principal bioactive polyphenol of turmeric (Curcuma longa), has demonstrated in vitro antifungal activity against Candida species and dermatophytes. It has been found to have antifungal effects that confirm its use alongside turmeric oil in antifungal preparations. Studies confirm its activity against C. albicans, and turmeric oil preparations containing curcumin and ar-turmerone have been validated against T. rubrum and other dermatophytes.
Curcumin, the principal polyphenol of turmeric, inhibits H. pylori growth in vitro across multiple clinical strains and suppresses H. pylori-induced NF-κB-mediated gastric inflammation. Animal studies confirm reduced gastritis activity. A small clinical trial showed significant symptom improvement and reduction of serologic gastric inflammation markers despite limited H. pylori eradication.
Curcumin, the active polyphenol in turmeric, has been identified in multiple reviews as capable of influencing GLP-1 release. It may inhibit DPP-4, the enzyme that degrades GLP-1, thereby prolonging GLP-1 activity. Evidence is primarily from in vitro and animal studies, with supporting human metabolic data.
Curcumin, the active polyphenol of turmeric, has been evaluated as an adjunct to scaling and root planing (SRP) in multiple RCTs. A 2025 systematic review confirmed its anti-inflammatory efficacy in periodontitis, reducing gingival indices, sulcus bleeding, and inflammatory biomarkers such as CRP. It inhibits NF-κB and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α relevant to periodontal pathogenesis.
Curcumin is the principal bioactive in turmeric with extensively documented gut microbiota-modulating properties, including promoting beneficial bacteria, reducing pathogenic species, and increasing SCFA production. Multiple preclinical and clinical studies confirm its bidirectional interaction with gut microbiota, where gut bacteria also transform curcumin into bioactive metabolites.
Curcumin, the principal bioactive of turmeric, has been specifically studied for its effects on the gut-brain axis. Research shows it attenuates gut inflammation, restores intestinal tight junction proteins, reduces neuroinflammation, and modulates gut microbiota composition. A dedicated study published in the Journal of Neurogastroenterology and Motility confirmed its therapeutic implications for the gut-brain axis.
Curcumin, the principal bioactive of turmeric, exhibits potent anti-inflammatory and antioxidant activity through NF-κB inhibition and Nrf2 activation. Peer-reviewed reviews published in BioMed Research International and Foods document its effects on aging-related molecular mechanisms and age-related diseases. Clinical trials in elderly populations show reductions in inflammatory biomarkers.
Curcumin has been investigated in multiple randomized controlled trials and systematic reviews for cardiovascular benefits, including improvements in endothelial function, lipid profiles, and inflammatory markers. Key mechanisms involve inhibition of NF-κB signaling, reduction of oxidative stress, and increased nitric oxide bioavailability. Evidence is promising but constrained by curcumin's poor oral bioavailability and the need for larger, longer-duration trials.
Curcumin (the active polyphenol of turmeric) has shown favorable effects on serum homocysteine in clinical trials. A 2021 systematic review (PMC8196702) covering animal studies and clinical trials found curcumin significantly reduced homocysteine in animal studies and showed favorable effects in human clinical trials, though with non-uniform results requiring further study.
Curcumin, the principal bioactive polyphenol of turmeric, enhances hepatic glucuronidation (Phase II estrogen conjugation), induces Nrf2-regulated Phase II detoxification enzymes (UGT, GST, NQO1), and reduces hepatic oxidative stress. It is explicitly listed in institutional reviews as an inducer of the Phase II glucuronidation pathway for hormone clearance.
Curcumin, the principal polyphenol in turmeric, inhibits tyrosinase and melanin synthesis, with in vitro studies in B16F10 melanoma cells demonstrating significant anti-melanogenic activity. It is listed in multiple systematic reviews as a natural depigmenting agent, though oral bioavailability is poor without enhanced formulations.
Curcumin has demonstrated IBS symptom improvement across multiple clinical studies. A 2025 umbrella review (Nutr Rev, 175 RCTs) specifically identified curcumin as improving IBS symptom severity. A 2024 real-world clinical study (Nutrients, n=146) found 93.1% of IBS patients reported symptom improvement with berberine/curcumin combination. Curcumin modulates intestinal inflammation, serotonergic signaling, and gut barrier integrity—key IBS mechanisms.
Curcumin has been tested in 13 placebo-controlled RCTs in IBD, with a 2025 meta-analysis demonstrating significant efficacy in achieving clinical remission and response in ulcerative colitis patients when used as adjunctive therapy. It targets NF-κB, oxidative stress, and gut microbiota modulation relevant to IBD. Evidence in Crohn's disease is inconclusive.
Curcumin, the principal curcuminoid from turmeric (Curcuma longa), improves insulin sensitivity by reducing inflammation, activating AMPK, inhibiting NF-κB, and modulating adipokines. An evidence-based review of human RCTs found curcumin improved glycaemic control in T2DM, and the NIH Endotext lists it among anti-diabetic herbs studied in clinical trials.
Curcumin, the active polyphenol of turmeric, is one of the most studied natural renoprotective agents. Multiple PMC systematic reviews confirm protective effects in diabetic nephropathy, chemotherapy-induced nephrotoxicity, and ischemia-reperfusion injury via Nrf2 induction, NF-kB inhibition, antioxidant, and antifibrotic mechanisms. It is named in the 2018 PubMed kidney stone review as an effective antioxidant phytophenol for urolithiasis prevention.
Curcumin, the primary bioactive curcuminoid of turmeric, has demonstrated renoprotective effects in multiple preclinical studies and some clinical trials, particularly for diabetic nephropathy and CKD. It reduces renal inflammation and oxidative stress via NF-κB and Nrf2 pathways. A meta-analysis of RCTs in diabetic nephropathy patients showed curcumin supplementation improved kidney function markers.
Curcumin, the principal polyphenol of turmeric, is identified in a PMC systematic review as one of the phytochemicals effective for urolithiasis prevention. Preclinical studies demonstrate curcumin reduces renal oxidative stress, inflammation, and calcium oxalate crystal deposition in animal models of induced nephrolithiasis by inhibiting crystal adhesion to renal tubular cells via antioxidant mechanisms.
Curcumin, the active polyphenol in turmeric, improves intestinal barrier function by modulating tight junction organization and reducing intestinal inflammation. A 2017 study in the American Journal of Physiology found curcumin modulated intracellular signaling and tight junction organization to improve barrier function. Multiple systematic reviews confirm anti-inflammatory GI benefits, though bioavailability is limited and tends to concentrate in the GI tract when absorbed.
Curcumin is the principal bioactive polyphenol of turmeric with extensively documented neuroprotective and anti-neuroinflammatory properties. An 18-month double-blind RCT (n=40 older adults) showed significant improvements in verbal and visual memory and attention with bioavailable curcumin. Multiple meta-analyses confirm cognitive benefits.
Curcumin, the primary bioactive polyphenol from turmeric, exerts hepatoprotective effects through antioxidant, anti-inflammatory (NF-κB inhibition), and antifibrotic (TGF-β/Smad modulation) mechanisms. Multiple RCTs and meta-analyses demonstrate significant reductions in ALT and AST in MAFLD patients. A 72-week RCT showed MASH resolution in 62% of patients receiving phospholipid curcumin 2g/day.
Curcumin is the primary bioactive polyphenol of turmeric, with preclinical and clinical evidence for anti-inflammatory activity in asthma, COPD, and cystic fibrosis. It reduces airway inflammation via NF-κB inhibition, decreases eosinophils, and may correct CFTR protein folding in cystic fibrosis models.
Curcumin, the primary bioactive curcuminoid of turmeric, exerts anti-VEGF, anti-inflammatory, and antioxidant activities directly relevant to AMD pathogenesis. A Phase 2 RCT (n=32, 24-month) found that curcumin alone and as part of the RQC combination reduced drusen volume versus untreated controls. A retrospective case-control study also showed a curcumin-based supplement combined with anti-VEGF injections improved functional outcomes in neovascular AMD.
Curcumin downregulates androgen receptor expression in hair follicle cells and reduces scalp inflammation via NF-κB suppression, countering DHT-driven follicular miniaturization. It is a core ingredient of Nutrafol, evaluated in AGA clinical trials. The 2025 Frontiers in Nutrition systematic review (10.3389/fnut.2025.1719711) identifies curcumin among dietary supplements with evidence for AGA benefit.
Curcumin inhibits mast cell degranulation by blocking Syk kinase, a pivotal enzyme in IgE-receptor signaling, reducing histamine, TNF-α, and IL-4 release. Murine allergy models confirm suppression of allergic responses and IgE-mediated mast cell activation. It is widely cited as a natural mast cell stabilizer in MCAS management protocols, though poor bioavailability requires enhanced delivery forms.
Topical curcumin (200 mg/pump every 8 hours for 3 days) was evaluated in a randomized, double-blind, placebo-controlled trial of 63 breastfeeding women with lactational mastitis. After 72 hours, the curcumin group showed significantly lower rates of moderate (p=0.019) and mild (p=0.002) mastitis and reduced pain, breast tension, and erythema. Multiple animal and cell-model studies further demonstrate curcumin suppresses NF-κB and inflammatory cytokines in mammary tissue.
Curcumin, the principal polyphenol of turmeric (Curcuma longa), has extensive preclinical evidence for neuroprotection and anti-amyloid activity. A 2018 UCLA double-blind RCT (n=40, age 51–84, 90 mg twice daily, 18 months) found curcumin significantly improved memory scores by 28% and attention versus placebo, with reduced amyloid and tau on PET imaging.
Multiple RCTs and a 2025 systematic review confirm curcumin reduces dysmenorrhea pain and PMS symptoms, with significant effects observed in triple-blind RCTs. Curcumin inhibits COX/LOX pathways, modulates prostaglandin synthesis, and has antioxidant activity. It is the primary active compound in turmeric responsible for anti-dysmenorrhea effects.
Curcumin, the principal bioactive polyphenol of Curcuma longa, has been investigated in multiple randomized controlled trials (RCTs) and several meta-analyses specifically in patients with metabolic syndrome (MetS). Clinical evidence shows it can favorably affect blood glucose, lipid levels, blood pressure, waist circumference, inflammatory markers, and insulin sensitivity. Results across trials are heterogeneous, and more high-quality RCTs are still needed to firmly establish optimal dosing and mechanisms.
Curcumin, the major polyphenol of turmeric, inhibits DNA methyltransferases (DNMTs) and modulates histone-modifying enzymes, altering promoter methylation patterns. A 2025 PMC systematic review (PMC12554032) identifies curcumin among the most frequently studied food-derived DNMT modulators. Evidence is primarily preclinical (in vitro and animal models).
Curcumin, the active polyphenol in turmeric, has been evaluated in RCTs for migraine. A double-blind placebo-controlled RCT found curcumin 500 mg twice daily for 8 weeks significantly reduced migraine attack duration and severity, and decreased serum CGRP levels. A meta-analysis of RCTs supported its role in migraine management.
Curcumin activates PGC-1α and AMPK/SIRT1 pathways to promote mitochondrial biogenesis and mitophagy. Studies in animal models demonstrate protection against mitochondrial dysfunction in cardiac, neural, and skeletal muscle tissues via upregulation of TFAM and NRF2. It reduces mitochondrial ROS and fragmentation under stress conditions.
Curcumin, the principal polyphenol of turmeric, has been studied in multiple animal models for protection against liver and immune damage caused by aflatoxin B1, ochratoxin A, deoxynivalenol, and zearalenone. It acts via NF-kB inhibition, NRF2 activation, antioxidant enzyme upregulation, and inhibition of AFB1-DNA adduct formation. Multiple peer-reviewed studies confirm significant protective effects against mycotoxin-induced hepatotoxicity, neuroinflammation, and immunosuppression.
Curcumin is supported by multiple RCTs and a 2025 structured narrative review showing consistent attenuation of post-exercise muscle damage markers (CK, IL-6), DOMS reduction, and improved recovery metrics. A 2025 RCT (n=34) found significant dose-response reductions in pain, CK, FORT, and IL-6 at 1500 mg/day.
Curcumin, the active polyphenol in turmeric, is supported by multiple RCTs and a 2022 systematic review and dose-response meta-analysis for reducing DOMS. A key RCT by Nicol et al. (2015) found moderate-to-large reductions in pain during DOMS assessment (VAS −1.4 to −1.7) at 24 and 48h post-exercise. A 2020 RCT found curcumin significantly reduced DOMS at 48 and 72h vs. placebo.
Curcumin, the primary bioactive of turmeric, crosses the blood-brain barrier and has been extensively studied for neuroprotection. Multiple clinical trials and meta-analyses demonstrate improvements in mood, memory, and biomarkers of neurodegeneration, mediated through anti-inflammatory and antioxidant mechanisms.
Curcumin, the principal polyphenol of turmeric, modulates neuroinflammatory pathways relevant to neuropathy through NF-κB inhibition and Nrf2 activation, reducing inflammatory cytokine expression and preserving nerve function in experimental neuropathy models. It has been used in traditional Ayurvedic and Chinese medicine for pain and inflammation for centuries. Combined DHA+curcumin has shown spinal cord neuroprotection in preclinical models.
Curcumin upregulates BDNF mRNA and protein expression in the hippocampus, promotes neurogenesis, increases dendritic spine density, and upregulates PSD-95 synaptic plasticity proteins. A 2025 Scientific Reports study demonstrated curcumin reversed cognitive deficits via BDNF/PSD-95 upregulation and dendritic growth in transgenic mice. Bioavailability is a key challenge requiring specialized formulations.
Curcumin, the active polyphenol from turmeric, has demonstrated significant bone-protective effects in preclinical models via OPG/RANKL, Wnt/β-catenin, and NF-κB signaling pathways. A 2025 meta-analysis of animal studies found curcumin significantly increased femoral and tibial BMD and improved trabecular microstructure. Clinical trials in postmenopausal osteoporosis show improved bone turnover markers when combined with standard therapy.
Multiple preclinical studies in rat and mouse models show curcumin inhibits NF-κB and AP-1 activation, reducing pancreatic inflammation in both ethanol and non-ethanol pancreatitis models. A small randomized pilot trial in tropical pancreatitis patients demonstrated significant reductions in oxidative stress markers (MDA) and increases in glutathione with 500 mg curcumin plus piperine for 6 weeks. More recent work shows curcumin ameliorates cerulein-induced chronic pancreatitis fibrosis via Nrf2/HO-1 signaling in mouse models.
Curcumin directly disrupts Giardia lamblia trophozoite structure by interfering with tubulin assembly, damaging the parasite's ventral disk and flagella. In vitro studies document activity against Plasmodium falciparum, Leishmania, and Toxoplasma gondii.
Curcumin, the principal bioactive polyphenol in turmeric, has been studied in Parkinson's disease for its ability to inhibit α-synuclein aggregation, reduce neuroinflammation, and modulate oxidative stress. A 2025 systematic review identified two RCTs and one cohort study in PD patients. Preclinical evidence is strong, but clinical translation is hampered by poor bioavailability.
Curcumin, the main polyphenol from turmeric, has been evaluated in multiple RCTs in PCOS, with a 2022 meta-analysis of 5 RCTs confirming significant reductions in BMI, fasting glucose, insulin, HOMA-IR, and total cholesterol. It reduces hyperandrogenism and oxidative stress via anti-inflammatory mechanisms.
Curcumin has been directly tested in a carrageenan-induced pleurisy rat model, where TPGS-stabilized curcumin nanoparticles significantly reduced pleural exudate volume and leukocyte count compared to controls. A separate study confirmed curcumin exerts antioxidant effects specifically in carrageenan-induced pleural inflammation. Ayurvedic tradition also uses curcumin-containing turmeric for pleurisy inflammation.
Curcumin, the principal bioactive of turmeric, has been evaluated in multiple RCTs for PMS and dysmenorrhea, with a 2025 systematic review of 10 RCTs finding that 6 reported significant PMS symptom improvement. Curcumin inhibits COX-2 and prostaglandin production and modulates inflammatory biomarkers and vitamin D status in PMS patients.
Curcumin, the principal polyphenol from turmeric, has demonstrated anti-inflammatory properties directly relevant to pneumonia via NF-κB inhibition and cytokine storm modulation. It is identified among natural antioxidants with therapeutic potential against COVID-19 viral pneumonia. Preclinical evidence supports its role in reducing lung inflammation in pneumonia models.
A 2006 pilot clinical study in 5 FAP patients showed curcumin (480 mg) combined with quercetin (20 mg) three times daily for 6 months reduced polyp number by 60.4% and size by 50.9% (both p<0.05). A subsequent Johns Hopkins double-blind RCT (n=44, 3,000 mg/day, 12 months) found no significant difference in polyp number or size vs. placebo when curcumin was used alone. Evidence for curcumin is strongest in combination with quercetin for FAP.
The principal bioactive polyphenol of turmeric, curcumin has multiple RCTs demonstrating reduction of inflammatory cytokines (CRP, IL-6, TNF-α) relevant to post-infectious inflammation resolution. RCTs in COVID-19 patients document shortened illness symptom duration. Traditional Ayurvedic use in convalescent care spans millennia.
Curcumin, the principal bioactive polyphenol of turmeric, reduces allergic rhinitis symptoms including rhinorrhea and nasal congestion associated with post-nasal drip. A pilot study published in Annals of Allergy, Asthma & Immunology found curcumin reduced nasal airflow resistance and improved sneezing and runny nose in perennial allergic rhinitis patients. Its mechanism involves NF-κB inhibition and reduced Th2 cytokine production driving mucus hypersecretion.
Curcumin, the active polyphenol in turmeric, inhibits NF-κB and COX-2 pathways, reducing post-surgical inflammation. Orthopaedic post-surgical reviews identify curcumin as a plant-based bioactive with anti-inflammatory and analgesic effects relevant to surgical recovery. Animal studies show it reduces neuronal apoptosis and oxidative damage after surgical injury.
Curcumin, the principal polyphenol of turmeric, has been included in post-viral recovery protocols for its potent anti-inflammatory and immunomodulatory effects. An integrative medicine review (Liebertpub, 2025) lists curcumin among important supplements for PASC management. Preclinical evidence shows curcumin attenuates chronic fatigue syndrome in animal models, and the Holistic Primary Care post-viral protocol includes curcumin-containing herbal combinations.
Curcumin, the principal bioactive polyphenol in turmeric (Curcuma longa), has been studied in RCTs as part of multi-ingredient prostate cancer protocols and is among the dietary compounds with evidence in prostate carcinogenesis pathways. The Pomi-T RCT showed significant PSA growth rate reduction using a blend containing curcumin. Preclinical studies show anti-androgenic, anti-proliferative, and pro-apoptotic effects on prostate cells.
Curcumin inhibits NF-κB and androgen receptor pathways in prostate cells, reducing inflammation and cell proliferation. A pilot RCT using bioavailability-enhanced curcumin with saw palmetto found significantly improved IPSS and Qmax versus placebo after 6 months. A 2019 systematic nutraceutical review confirmed clinical study evidence of curcumin's efficacy on BPH-associated LUTS symptoms.
Curcumin, the primary bioactive polyphenol from turmeric, has been evaluated in multiple RCTs and a meta-analysis for psoriasis. A 2022 meta-analysis of seven clinical RCTs found that curcumin monotherapy significantly improved PASI scores versus placebo, and combination therapy with conventional treatment produced additional benefit. It acts via NF-κB, IL-17, and IL-23 pathway inhibition.
Curcumin, the principal bioactive in turmeric, has anti-inflammatory and mast cell-modulating properties studied in chronic urticaria. It is specifically identified in a 2025 Sage systematic review as a key bioactive in commercially available herbal urticaria remedies. Clinical trials involving curcumin-containing Curcuma longa formulations have shown promising results for reducing chronic urticaria symptoms.
Curcumin, the active polyphenol from turmeric, inhibits COX-2, 5-LOX, NF-κB, and multiple pro-inflammatory cytokines implicated in RA. A 2025 network meta-analysis of 18 RCTs found curcumin superior to placebo in reducing swollen and tender joint counts and inflammatory markers. Typical effective dose is 500–1000 mg/day of standardized extract.
Curcumin, the primary polyphenol of turmeric, inhibits NF-κB, COX-2, and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) implicated in rosacea. Reviewed in J Drugs Dermatol 2018 (PMID 29879248) as a biologically-based rosacea therapy. Active compound in the polyherbal RCT that reduced rosacea facial redness by 40%.
Curcumin has been identified in systematic reviews and preclinical/clinical studies as an anti-scarring agent. It suppresses TGF-β/Smad and NF-κB signaling, reduces excessive collagen deposition in hypertrophic scars, and showed benefit in one RCT for scar management.
Curcumin, the primary bioactive compound in turmeric, has been studied in sciatic nerve injury models and low back pain clinical trials. It inhibits NF-κB, COX-2, TNF-α, and IL-6, reduces neuropathic allodynia in animal models, and promotes sciatic nerve regeneration. A randomized clinical trial combining curcumin with Boswellia significantly reduced chronic lower back pain versus placebo.
Curcumin, the active compound in turmeric, is a potent anti-inflammatory agent that reduces joint, disc, and muscular inflammation associated with scoliosis—particularly back pain and stiffness in adult/degenerative scoliosis. It is included in scoliosis management protocols for reducing pro-inflammatory cytokines relevant to disease progression pathways, and is noted in scoliosis-specific clinical nutrition reviews.
Curcumin, the bioactive phenol of turmeric, reduces nasal mucosal inflammation via NF-κB and COX/LOX pathway inhibition, with demonstrated efficacy in murine allergic rhinitis models for reducing nasal symptoms and eosinophil infiltration. A pilot RCT testing curcumin nasal spray in perennial allergic rhinitis patients showed improvements in nasal congestion and airflow scores. Bioavailability is low without piperine co-administration.
Curcumin, the primary polyphenol from turmeric (Curcuma longa), has in vitro and emerging clinical evidence for stimulating collagen synthesis in skin fibroblasts, inhibiting MMP-1 and MMP-9, and reducing oxidative stress that degrades collagen. It has centuries-long traditional use in Ayurvedic medicine for skin wound healing and anti-inflammatory skin applications.
Curcumin, the active polyphenol in turmeric, demonstrates anti-inflammatory and antioxidant properties with evidence for musculoskeletal conditions. It reduces exercise-induced muscle damage markers and has been studied in combination with bromelain and other agents for soft tissue injury recovery.
Curcumin from turmeric has documented anti-inflammatory, antioxidant, and potential photoprotective effects, including inhibition of UV-induced melanoma cell proliferation in vitro and chemopreventive activity against UV-induced skin damage. It is listed among documented photochemoprotective phytochemicals in Afaq and Mukhtar's authoritative review.
Curcumin has been studied specifically in TMJ osteoarthritis in both in vitro and animal models, demonstrating inhibition of cartilage-degrading enzymes (MMP-1, MMP-3, MMP-9, MMP-13), inflammatory mediators (IL-6, iNOS, COX-2), and protection of TMJ chondrocytes via the Nrf2/ARE pathway. It is cited in TMJ/TMD supplement literature as an anti-inflammatory agent.
Curcumin, the active polyphenol in turmeric, inhibits NF-κB and COX-2 pathways, reducing pulpal inflammation. A 2013 PMC review documented traditional use for dental pain and confirmed its anti-inflammatory, antimicrobial, and antiseptic properties for oral applications. A 2025 PMC systematic review ranked curcumin among the top three phytotherapeutic analgesics for dental pain. Clinical studies show curcumin gel as an adjunct for periodontal and pulpal pain management.
Curcumin, the principal bioactive polyphenol in turmeric, has been shown in multiple meta-analyses of RCTs to significantly reduce serum triglycerides. One meta-analysis found TG reductions of −0.57 mmol/L; another in NAFLD patients found TG decreased by −0.49 mmol/L vs. placebo. Bioavailability-enhanced formulations show stronger effects.
Curcumin is the principal active constituent of turmeric with documented anti-H. pylori, anti-inflammatory, and gastric mucosal-protective effects. An RCT found curcumin adjunct therapy improved dyspepsia in peptic ulcer patients. Animal studies consistently show reduced gastric ulcer index. Early uncontrolled clinical data showed 76% ulcer healing at 12 weeks with high-dose curcumin.
Curcumin, the principal polyphenol from turmeric, has demonstrated anti-uterine fibroid and anti-endometriosis activity in multiple preclinical studies. It inhibits leiomyoma cell proliferation via PPARγ activation, arrests endometriosis by downregulating MMP-9, reduces estradiol production in endometriotic cells, and protects uterine myometrium from oxidative damage. Human clinical trials are still needed.
Curcumin is a polyphenol from turmeric with documented broad-spectrum antiviral activity against HIV-1, HIV-2, HSV, HPV, HTLV-1, HBV, HCV, influenza A, Japanese encephalitis virus, and SARS-CoV-1/2. An RCT in early-stage COVID-19 showed clinical benefit of curcumin plus quercetin supplementation alongside standard of care.
Curcumin, the primary polyphenol in turmeric, has anti-inflammatory, antioxidant, and Nrf2-activating properties studied in vitiligo. Multiple peer-reviewed herbal treatment reviews for vitiligo include curcumin as a plant compound with mechanistic relevance, including Nrf2 pathway activation that protects melanocytes from oxidative damage. In vitro studies confirm curcumin reduces H2O2-induced melanocyte oxidative damage.
Curcumin, the principal curcuminoid of turmeric, has extensive preclinical and growing clinical evidence for wound healing. It enhances granulation tissue formation, collagen deposition, and wound contraction while suppressing inflammatory cytokines. A 2025 scoping review of clinical trials confirmed consistent wound-healing efficacy across multiple wound types.
Curcumin, the principal bioactive polyphenol of turmeric, inhibits 5-alpha reductase and NF-kB-mediated scalp inflammation in preclinical models. It has a long traditional use in Ayurvedic medicine for scalp health. Some in vitro and animal data support its anti-androgenic and anti-inflammatory actions relevant to hair loss, though human clinical trials are limited.
Curcumin, the primary bioactive in turmeric, has anti-inflammatory properties (NF-κB inhibition, cytokine suppression) directly relevant to sinus mucosal inflammation. Traditional Ayurvedic use for sinus conditions is established; clinical RCTs specific to sinusitis are lacking.
Volver